Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Cancer Discov. 2016 Apr 13;6(6):664–679. doi: 10.1158/2159-8290.CD-16-0040

Figure 4. Tocilizumab improves hypercytokinemia in patients with severe CRS.

Figure 4

14 of 51 patients developed severe CRS and all were treated with tocilizumab. Cytokines were measured serially. Figure 4 depicts the levels of 4 cytokines starting from day of infusion over the first month. Hashed lines depict time of tocilizumab administration. After tocilizumab treatment, there was generally an apparent transient rise in IL6, followed by a rapid decrease. INFγ also decreased rapidly after tocilizumab administration in most patients. sIL6R increased in all and sgp130 levels increased in most patients after tocilizumab